Short answer
Aquestive Therapeutics, Inc. (AQST) filed an 8-K current report with the SEC on October 14, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Exclusive U.S. commercialization rights granted to Eton for LIBERVANT, subject to FDA approvals.
Aquestive Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Exclusive U.S. commercialization rights granted to Eton for LIBERVANT, subject to FDA approvals
- $10.0M upfront fee received, with up to $47.5M in regulatory and commercial milestones
- Mid-teens royalties on annual U.S. net sales, creating ongoing revenue participation
- Aquestive remains exclusive manufacturer and supplier under a 20-year initial supply term
- Commercial launch depends on full FDA approval, including potential expansion to ages 2–5 and 6–11
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aquestive Therapeutics, Inc. 8-K filings
Get the next AQST 8-K as it lands
Follow AQST for push alerts, or ask the research agent what this filing means.